

GlaxoSmithKline - Relovair - Crosses the safety hurdle, while needs more data on the efficacy front

https://marketpublishers.com/r/G1F5E31EE3FEN.html

Date: January 2012 Pages: 3 Price: US\$ 90.00 (Single User License) ID: G1F5E31EE3FEN

Abstracts

GSK and Theravance jointly announced their completion of pivotal studies of once daily Relovair and their intention to file Relovair globally for COPD (100/25 mcg dose) and in Europe for Asthma indications by mid-2012. The announced data shows that on efficacy, Relovair is better than its individual components and comparable to Seretide/Advair (24 hr mean FEV1) while there are no safety concerns. We believe the non-pivotal study comparing Relovair to Advair in Asthma (n=500 patients, 24 weeks) was relatively smaller and shorter for the clinical implications of the compliance benefit to be reflected in patient benefit/outcome. Based on GSK's confidence on regulatory filing, it seems there are unlikely to be any safety concerns (except fatal pneumonia reported with higher dose regimen-200/25 mcg). Company is planning to conduct OUTCOME study with 16000 patients to prospectively evaluate the effect of Relovair compared with placebo on survival in COPD patients with a history of or at risk from CV disease.



Contents

COMPANIES MENTIONED

GlaxoSmithKline



I would like to order

Product name: GlaxoSmithKline - Relovair - Crosses the safety hurdle, while needs more data on the efficacy front

Product link: https://marketpublishers.com/r/G1F5E31EE3FEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G1F5E31EE3FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



GlaxoSmithKline - Relovair - Crosses the safety hurdle, while needs more data on the efficacy front